Overview
HD PCI is a multicenter, randomized, registry-based, cluster crossover design trial of higher dose versus lower dose heparin in patients undergoing elective percutaneous coronary intervention (PCI).
Description
The primary objective of HD PCI is to compare the effect of a policy of higher dose heparin (100 U/kg) use to a policy of lower dose heparin (70 U/kg) use on death, myocardial infarction (MI) or target vessel revascularization (TVR) in patients undergoing elective percutaneous coronary intervention (PCI).
Eligibility
Inclusion Criteria:
- Patients undergoing elective PCI
Exclusion Criteria:
- Age <18 years
- Planned chronic total occlusion PCI
- Non-resident precluding follow up through local registries
Hospital (Cluster) Eligibility Criteria
Hospitals will be eligible to participate if they meet the following criteria:
- Submit PCI procedure data to a compatible registry that is able to provide data for the trial
- Site agrees to manage patients as per the higher or lower dose heparin policy in place during the given crossover period